BRPI0818448A2 - Composto, composição farmacêutica, uso de um composto, e, métodos para o tratamento ou prevenção de um distúrbio madiano pelo receptor mglur5. - Google Patents

Composto, composição farmacêutica, uso de um composto, e, métodos para o tratamento ou prevenção de um distúrbio madiano pelo receptor mglur5.

Info

Publication number: BRPI0818448A2
Authority: BR; Brazil
Prior art keywords: compound; madian; disorder; treating; preventing
Prior art date: 2007-10-19

Application number

Other languages

English (en)

Inventor

Erwan Arzel

Louise Edwards

Methvin Isaac

Donald A Mcleod

Abdelmalik Slassi

Tao Xin

Original Assignee

Astrazeneca Ab

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2007-10-19

Filing date

2008-10-17

Publication date

2015-05-12

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40567640&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BRPI0818448(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2008-10-17 Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab

2015-05-12 Publication of BRPI0818448A2 publication Critical patent/BRPI0818448A2/pt

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/14—Antitussive agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings

Landscapes

Health & Medical Sciences (AREA)
Organic Chemistry (AREA)
Chemical & Material Sciences (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Chemical Kinetics & Catalysis (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Animal Behavior & Ethology (AREA)
Life Sciences & Earth Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Biomedical Technology (AREA)
Neurosurgery (AREA)
Neurology (AREA)
Pain & Pain Management (AREA)
Diabetes (AREA)
Psychiatry (AREA)
Ophthalmology & Optometry (AREA)
Rheumatology (AREA)
Cardiology (AREA)
Heart & Thoracic Surgery (AREA)
Obesity (AREA)
Hematology (AREA)
Pulmonology (AREA)
Psychology (AREA)
Urology & Nephrology (AREA)
Hospice & Palliative Care (AREA)
Vascular Medicine (AREA)
Endocrinology (AREA)
Child & Adolescent Psychology (AREA)
Emergency Medicine (AREA)
Immunology (AREA)
Orthopedic Medicine & Surgery (AREA)
Physical Education & Sports Medicine (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

BRPI0818448 2007-10-19 2008-10-17 Composto, composição farmacêutica, uso de um composto, e, métodos para o tratamento ou prevenção de um distúrbio madiano pelo receptor mglur5. BRPI0818448A2 (pt)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US98129407P	2007-10-19	2007-10-19
PCT/SE2008/051170 WO2009051556A1 (en)	2007-10-19	2008-10-17	Tetrazole derivatives as modulators of metabotropic glutamate receptors (mglurs)

Publications (1)

Publication Number	Publication Date
BRPI0818448A2 true BRPI0818448A2 (pt)	2015-05-12

Family

ID=40567640

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
BRPI0818448 BRPI0818448A2 (pt)	2007-10-19	2008-10-17	Composto, composição farmacêutica, uso de um composto, e, métodos para o tratamento ou prevenção de um distúrbio madiano pelo receptor mglur5.

Country Status (21)

Country	Link
US (1)	US7960422B2 (pt)
EP (1)	EP2231647A4 (pt)
JP (1)	JP2011500673A (pt)
KR (1)	KR20100090777A (pt)
CN (1)	CN101896480A (pt)
AR (1)	AR068921A1 (pt)
AU (1)	AU2008312055A1 (pt)
BR (1)	BRPI0818448A2 (pt)
CA (1)	CA2703425A1 (pt)
CL (1)	CL2008003085A1 (pt)
CO (1)	CO6321281A2 (pt)
CR (1)	CR11376A (pt)
DO (1)	DOP2010000119A (pt)
EA (1)	EA201000654A1 (pt)
IL (1)	IL204958A0 (pt)
MX (1)	MX2010004272A (pt)
PE (1)	PE20090875A1 (pt)
TW (1)	TW200934771A (pt)
UY (1)	UY31403A1 (pt)
WO (1)	WO2009051556A1 (pt)
ZA (1)	ZA201002694B (pt)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
EP1847543A1 (de)	2006-04-19	2007-10-24	Boehringer Ingelheim Pharma GmbH & Co. KG	Dihydrothienopyrimidine zur Behandlung von entzündlichen Erkrankungen
US8754073B2 (en)	2007-10-19	2014-06-17	Boehringer Ingelheim International Gmbh	Substituted piperazino-dihydrothienopyrimidines
EP2205609B1 (de)	2007-10-19	2017-03-29	Boehringer Ingelheim International GmbH	Heterocyclus-substituierte piperazino-dihydrothienopyrimidine
US8486948B2 (en)	2007-10-19	2013-07-16	Boehringer Ingelheim International Gmbh	Piperazinodihydrothienopyrimidine derivatives
KR20130105914A (ko)	2008-09-22	2013-09-26	카이맨 케미칼 컴파니 인코포레이티드	Ｈ-ｐｇｄｓ 억제제로서 다중헤테로아릴 화합물 및 프로스타글란딘 ｄ2 매개된 질병의 치료를 위한 그의 용도
CN102256967A (zh) *	2008-12-18	2011-11-23	阿斯利康(瑞典)有限公司	制备3-{4-甲基-5-[(1r)-1-(2-(3-甲基苯基-2h-四唑-5-基)-乙氧基]-4h-[1,2,4]三唑-3-基}-吡啶、4-甲基-3-甲基硫基-5-(吡啶-3-基)-1,2,4-三唑和(1r)-1-[2-(3-甲基苯基)-2h-四唑-5-基]乙醇的方法
EP2438052A1 (en) *	2009-06-05	2012-04-11	Oslo University Hospital HF	Azole derivatives as wtn pathway inhibitors
CA2820800A1 (en)	2010-12-08	2012-06-14	Oslo University Hospital Hf	Triazole derivatives as wnt signaling pathway inhibitors
BR112013023813A2 (pt)	2011-03-18	2016-12-13	Novartis Ag	combinações de ativadores do receptor acetilcolina nicotínico alfa 7 e antagonistas de mglur5 para uso em dopamina induzida por discinesia na doença de parkinson
US20130059866A1 (en)	2011-08-24	2013-03-07	Boehringer Ingelheim International Gmbh	Novel piperidino-dihydrothienopyrimidine sulfoxides and their use for treating copd and asthma
US9802954B2 (en)	2011-08-24	2017-10-31	Boehringer Ingelheim International Gmbh	Piperidino-dihydrothienopyrimidine sulfoxides and their use for treating COPD and asthma
CN106032377A (zh) *	2015-03-12	2016-10-19	天津药物研究院有限公司	四氮唑类urat1抑制剂、制备方法及其在高尿酸血症和痛风治疗上的用途

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4663332A (en) *	1985-10-10	1987-05-05	Hoffman-La Roche Inc.	5-substituted N-alkylated tetrazoles
WO1993002677A1 (en)	1991-08-03	1993-02-18	Smithkline Beecham Plc	5-ht4 receptor antagonists
DE10023430A1 (de)	2000-05-12	2001-11-15	Bayer Ag	Substituierte N-Benzoyl-N'-(tetrazolylphenyl)-harnstoffe
GB0115862D0 (en)	2001-06-28	2001-08-22	Smithkline Beecham Plc	Compounds
GB0121033D0 (en)	2001-08-30	2001-10-24	Novartis Ag	Organic compounds
JP4303109B2 (ja)	2001-10-04	2009-07-29	メルクエンドカムパニーインコーポレーテッド	代謝共役型グルタミン酸受容体−５のヘテロアリール置換テトラゾール調節剤
EP1485093B1 (en)	2002-03-12	2010-11-03	Merck Sharp & Dohme Corp.	Di-aryl substituted tetrazole modulators of metabotropic glutamate receptor-5
CA2494987C (en) *	2002-08-09	2012-04-17	Astrazeneca Ab	Isoxazoles and their use as modulators of metabotropic glutamate receptor-5
WO2005077345A1 (en) *	2004-02-03	2005-08-25	Astrazeneca Ab	Compounds for the treatment of gastro-esophageal reflux disease
CA2555272A1 (en)	2004-02-18	2005-09-01	Astrazeneca Ab	Polyheterocyclic compounds and their use as metabotropic glutamate receptor antagonists
RU2372347C2 (ru) *	2004-02-18	2009-11-10	Астразенека Аб	Соединения тетразола и их применение в качестве антагонистов метаботропного рецептора глутамата
TW200604183A (en) *	2004-02-18	2006-02-01	Astrazeneca Ab	Triazole compounds and their use as metabotropic glutamate receptor antagonists
US7585881B2 (en) *	2004-02-18	2009-09-08	Astrazeneca Ab	Additional heteropolycyclic compounds and their use as metabotropic glutamate receptor antagonists
UY29796A1 (es)	2005-09-29	2007-04-30	Astrazeneca Ab	Nuevos compuestos para el tratamiento de trastornos neurológicos, psiquiátricos o del dolor
TW200811157A (en)	2006-05-05	2008-03-01	Astrazeneca Ab	mGluR5 modulators I
TW200811156A (en)	2006-05-05	2008-03-01	Astrazeneca Ab	mGluR5 modulators IV

2008
- 2008-10-17 CA CA2703425A patent/CA2703425A1/en not_active Abandoned
- 2008-10-17 EP EP08840285A patent/EP2231647A4/en not_active Withdrawn
- 2008-10-17 JP JP2010529900A patent/JP2011500673A/ja active Pending
- 2008-10-17 US US12/285,988 patent/US7960422B2/en not_active Expired - Fee Related
- 2008-10-17 AR ARP080104548A patent/AR068921A1/es unknown
- 2008-10-17 UY UY31403A patent/UY31403A1/es unknown
- 2008-10-17 WO PCT/SE2008/051170 patent/WO2009051556A1/en not_active Ceased
- 2008-10-17 KR KR1020107010834A patent/KR20100090777A/ko not_active Withdrawn
- 2008-10-17 TW TW097139967A patent/TW200934771A/zh unknown
- 2008-10-17 PE PE2008001783A patent/PE20090875A1/es not_active Application Discontinuation
- 2008-10-17 BR BRPI0818448 patent/BRPI0818448A2/pt not_active IP Right Cessation
- 2008-10-17 CL CL2008003085A patent/CL2008003085A1/es unknown
- 2008-10-17 MX MX2010004272A patent/MX2010004272A/es not_active Application Discontinuation
- 2008-10-17 AU AU2008312055A patent/AU2008312055A1/en not_active Abandoned
- 2008-10-17 EA EA201000654A patent/EA201000654A1/ru unknown
- 2008-10-17 CN CN2008801179810A patent/CN101896480A/zh active Pending
2010
- 2010-04-08 IL IL204958A patent/IL204958A0/en unknown
- 2010-04-16 ZA ZA2010/02694A patent/ZA201002694B/en unknown
- 2010-04-19 DO DO2010000119A patent/DOP2010000119A/es unknown
- 2010-04-19 CR CR11376A patent/CR11376A/es not_active Application Discontinuation
- 2010-04-28 CO CO10050285A patent/CO6321281A2/es not_active Application Discontinuation

Also Published As

Publication number	Publication date
KR20100090777A (ko)	2010-08-17
US7960422B2 (en)	2011-06-14
CN101896480A (zh)	2010-11-24
EA201000654A1 (ru)	2010-12-30
IL204958A0 (en)	2010-11-30
AR068921A1 (es)	2009-12-16
US20090131454A1 (en)	2009-05-21
WO2009051556A1 (en)	2009-04-23
CR11376A (es)	2010-07-19
AU2008312055A1 (en)	2009-04-23
UY31403A1 (es)	2009-05-29
DOP2010000119A (es)	2010-05-31
PE20090875A1 (es)	2009-08-08
ZA201002694B (en)	2011-03-30
CO6321281A2 (es)	2011-09-20
EP2231647A4 (en)	2011-08-31
EP2231647A1 (en)	2010-09-29
MX2010004272A (es)	2010-04-30
JP2011500673A (ja)	2011-01-06
CA2703425A1 (en)	2009-04-23
CL2008003085A1 (es)	2009-10-09
TW200934771A (en)	2009-08-16

Publication	Publication Date	Title
BRPI0818448A2 (pt)	2015-05-12	Composto, composição farmacêutica, uso de um composto, e, métodos para o tratamento ou prevenção de um distúrbio madiano pelo receptor mglur5.
BRPI0818244A2 (pt)	2015-06-16	Composto, composição farmacêutica, uso de um composto, e, método para tratamento de um distúrbio ou doença
BRPI0814777A2 (pt)	2015-03-03	Composto, composição farmacêutica, método para tratar um neoplasma, uso de um composto, e, composição farmacêutica.
BRPI0816881A2 (pt)	2015-03-17	Composto, composição farmacêutica, uso de um composto, e, métodos para tratar doenças ou distúrbios e para preparar um composto.
BRPI0815709A2 (pt)	2017-06-13	composro, composição farmacêutica, e, uso de um composto.
BRPI0913585A2 (pt)	2015-10-27	composto, método para fabricar um composto, composição farmacêutica, uso de um composto, e, método para o tratamento ou prevenção de distúrbios
BRPI0917458A2 (pt)	2015-12-01	composto, método de tratamento de doenças e condições, composição farmacêutica, método para tratar ou prevenir doença, e, uso de um composto
BRPI0922475A2 (pt)	2017-06-06	composto, composição farmacêutica , método para tratar câncer, e, uso de um composto.
BRPI0917705A2 (pt)	2016-02-16	composto, pró-droga, composição farmacêutica, método para tratar ou prevenir uma doença ou condição, e, uso do composto
BRPI0813237A2 (pt)	2014-12-23	Composto, método para preparar o composto, composição, medicamento, e, uso do composto.
BRPI0907976A2 (pt)	2015-08-04	Composto, composição farmacêutica, uso de um composto, e, método para tratar ou prevenir doenças
CL2007002974A1 (es)	2008-05-23	Compuestos derivados de benzoimidazol; composicion farmaceutica; y uso para el tratamiento de trastornos asociados con dgat1.
BRPI0814593A2 (pt)	2015-01-20	Composto, composição farmacêutica que o contém e uso do composto.
CL2007002431A1 (es)	2008-03-14	Compuestos derivados de azabenzotiofenil; composicion farmaceutica; y uso para la inhibicion del crecimiento celular anomalo o de tratamiento de un trastorno hiperproliferativo.
BRPI0821299A2 (pt)	2015-06-16	Composto, processo para preparar o mesmo, composição farmacêutica, processo para preparar a mesma, uso de um composto, e, método para tratar, ou reduzir o risco de, uma doença ou condição.
CL2007003803A1 (es)	2008-08-01	Compuestos derivados de sulfonamidas; procedimiento de preparacion; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento del cancer, dislipidemia, diabetes, obesidad, infeccion.
BRPI0716171A2 (pt)	2013-09-17	composto, composiÇço farmacÊutica e uso de um composto.
BRPI0819755A2 (pt)	2018-07-17	composto, composição farmacêutica, processos para a preparação de um composto e de uma composição farmacêutica, uso de um composto, e, método para tratar ou reduzir o risco de uma doença ou uma condição inflamatória
BRPI0811635A2 (pt)	2014-11-11	Compostos de arilazol-2-il cianoetilamino, métodos para fazê-los e métodos para o uso dos mesmos
CL2007003202A1 (es)	2008-03-07	Compuestos derivados de espiroindolinona; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento de trastornos de proliferacion celular.
BRPI0914802A2 (pt)	2015-08-11	Composto, pró-droga, medicamento, uso do composto ou uma pró-droga de mesmo.
BRPI0907230A2 (pt)	2019-09-24	composto, prodroga do composto, fármaco, método para tratar ou prevenir uma doença associada com as funções de um receptor de crf, e, uso do composto
CL2007003049A1 (es)	2008-05-16	Compuestos derivados de 2,4-diaminopirimidina; composicion farmaceutica, utiles para tratar trastornos proliferativos.
CL2008001049A1 (es)	2008-08-08	Compuestos derivados de benzamidas sustituidas; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento de la diabetes, intolerancia a la glucosa, dislipidemia, hipertension, obesidad.
BRPI0907974A2 (pt)	2015-08-04	Composto, composição farmacêutica, uso de um composto, e, método para tratar ou prevenir doenças

Legal Events

Date	Code	Title	Description
2015-12-01	B08F	Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]	Free format text: REFERENTE AS 4A, 5A, 6A E 7A ANUIDADES.
2016-04-05	B08K	Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]	Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2343 DE 01-12-2015 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.